ASSOCIATION OF MYOSITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS - CASE REPORT

ASSOCIATION OF MYOSITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS - CASE REPORT

FERREIRA, LÍGIA LAVEZO; MORETE, VISLAINE AGUIAR; CARVALHO, CAROLINA PELLISON; SILVEIRA, OTAVIO LEÃO DA; GAGGINI, MÁRCIO CÉSAR REINO; SILVA, APARECIDA MEIRA DA; SILVA, TAISA MORETE DA

Pôster:

Systemic lupus erythematosus (SLE) is a severe autoimmune disease, with many clinical manifestations. Myositis has traditionally been recognized as a feature in SLE, and it is a heterogeneous condition. Clinical manifestations include muscle weakness associated with increased levels of creatine phosphokinase (CPK).

Case report

A 38-year-old woman, attended the rheumatology clinic of Universidade Brasil, complaining of migratory and asymmetric polyarthralgia, without morning stiffness, which 3 months ago has evolved to loss of strength of the scapular and pelvic girdle. At clinical examination, was observed strength grade 3 in upper limbs and grade 4 in lower limbs; without phlogistic signs in joints. Laboratory tests showed positive antinuclear factor (ANF), with coarse speckled pattern (1:640), CPK of 6416 U/L, erythrocyte sedimentation rate (ESR) of 90mm, C-reactive protein (PCR) of 31.2 mg/L, oxaloacetic transaminase (GOT) of 198 U/L, Glutamate-Pyruvate Transaminase (GPT) of 184 U/L, Lactic Acid Dehydrogenase (LDH) of 1636 U/L, Aldolase of 23.5 U/L, and computed tomography (CT) showed right pleural effusion. The diagnostic hypothesis was polymyositis and lupus. Treatment was performed with methylprednisolone pulse therapy for 3 days, with significant improvement of the symptoms, with significant improvement of the symptoms, being discharged with prednisone 60 mg prednisone a day. Moreover, the patient presented results of the Anti-SM reagent and complement consumption of C3, C4 and CH50. Treatment with hydroxychloroquine and methotrexate was started, presenting symptom control.

Conclusion

True myositis is relatively rare and failure to identify in cases of SLE, with a the prevalence varies from 4% to 16% in SLE. The significant association of active disease with myositis suggests that organ damage promote the progression of myositis in lupus patients.

Systemic lupus erythematosus (SLE) is a severe autoimmune disease, with many clinical manifestations. Myositis has traditionally been recognized as a feature in SLE, and it is a heterogeneous condition. Clinical manifestations include muscle weakness associated with increased levels of creatine phosphokinase (CPK).

Case report

A 38-year-old woman, attended the rheumatology clinic of Universidade Brasil, complaining of migratory and asymmetric polyarthralgia, without morning stiffness, which 3 months ago has evolved to loss of strength of the scapular and pelvic girdle. At clinical examination, was observed strength grade 3 in upper limbs and grade 4 in lower limbs; without phlogistic signs in joints. Laboratory tests showed positive antinuclear factor (ANF), with coarse speckled pattern (1:640), CPK of 6416 U/L, erythrocyte sedimentation rate (ESR) of 90mm, C-reactive protein (PCR) of 31.2 mg/L, oxaloacetic transaminase (GOT) of 198 U/L, Glutamate-Pyruvate Transaminase (GPT) of 184 U/L, Lactic Acid Dehydrogenase (LDH) of 1636 U/L, Aldolase of 23.5 U/L, and computed tomography (CT) showed right pleural effusion. The diagnostic hypothesis was polymyositis and lupus. Treatment was performed with methylprednisolone pulse therapy for 3 days, with significant improvement of the symptoms, with significant improvement of the symptoms, being discharged with prednisone 60 mg prednisone a day. Moreover, the patient presented results of the Anti-SM reagent and complement consumption of C3, C4 and CH50. Treatment with hydroxychloroquine and methotrexate was started, presenting symptom control.

Conclusion

True myositis is relatively rare and failure to identify in cases of SLE, with a the prevalence varies from 4% to 16% in SLE. The significant association of active disease with myositis suggests that organ damage promote the progression of myositis in lupus patients.

Palavras-chave:

DOI: 10.5151/sbr2019-033

Referências bibliográficas

• [1]

Como citar:

FERREIRA, LÍGIA LAVEZO; MORETE, VISLAINE AGUIAR; CARVALHO, CAROLINA PELLISON; SILVEIRA, OTAVIO LEÃO DA; GAGGINI, MÁRCIO CÉSAR REINO; SILVA, APARECIDA MEIRA DA; SILVA, TAISA MORETE DA; "ASSOCIATION OF MYOSITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS - CASE REPORT", p-33-33. In: Anais do 36º Congresso Brasileiro de Reumatologia. [ISBN 978-85-212-1892-0]. São Paulo: Blucher, 2019.
ISSN 23577282, DOI 10.5151/sbr2019-033